Testing a new stroke drug: different doses for people who cannot get standard care
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a new medication (bevifibatide) to see which dose works best for people having an ischemic stroke who cannot get standard treatments like clot-busting drugs or a procedure to remove the clot. It aims to improve recovery by stopping clots from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a stroke caused by a blood clot (ischemic stroke) but you cannot get standard clot-busting drugs or a procedure to remove the clot, or those treatments did not help enough.
- Your stroke symptoms are at least moderately severe (score of 3 or more on the NIH stroke scale).
- A brain scan (CTA or MRA) shows no large or medium-sized blocked artery — any blockage is either very small or in tiny branches.
- You do not have a known heart condition like atrial fibrillation or a recent heart attack that could send clots to the brain.
- You are not planning to take two blood thinners (like aspirin plus another) within the first week after stroke.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a clot-dissolving medicine (alteplase or tenecteplase) is safe and effective for people who have had a stroke and are taking a blood thinner (DOAC) like apixaban or rivaroxaban. It aims to see if this treatment can still be given within a few hours of the stroke.
This trial tests whether giving IV TNK (tenecteplase) plus standard stroke care can improve outcomes in some people who have a new stroke but cannot get alteplase (another clot-busting drug) and do not have a large blocked artery that can be treated with a procedure. It’s meant for strokes with “mismatch” findings on scans that suggest salvageable brain tissue.
This trial tests a new medicine called SP-8203 added to standard clot-busting treatment for people having a moderate to severe stroke. The goal is to see if it helps improve recovery and is safe.
This trial checks if adding an interleukin-6 receptor inhibitor (a drug that reduces inflammation) to standard emergency clot removal can improve recovery for people with a severe stroke affecting the back part of the brain (posterior circulation). It is for patients who need urgent treatment within 24 hours of symptom onset.
This trial tests if a procedure to remove a large blood clot from the brain (called a thrombectomy) can help people with severe strokes who have a large damaged area. It is for people who can be treated within 24 hours of their stroke starting.
This trial tests a medication called tirofiban given intravenously after standard thrombolysis to see if it improves recovery in people with acute ischemic stroke. It is for those whose symptoms have not improved or are getting worse after initial treatment.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.